Diabetes

28 January 2013

FDA approves new diabetes drugs

The US Food and Drug Administration late Friday approved three new medications to help people battle type 2 diabetes.

0

The US Food and Drug Administration  approved three new medications to help people battle type 2 diabetes.

All three drugs contain a new active ingredient, alogliptin, either alone or in combination with other, previously approved medications. The newly approved drugs include Nesina (alogliptin), Kazano (alogliptin plus metformin) and Oseni (alogliptin plus pioglitazone), the FDA said in a news release.

"Controlling blood sugar levels is very important in the overall treatment and care of diabetes," Dr Mary Parks, director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, said in the statement. "Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control."

People living with type 2 diabetes

More than 24 million people in the United States are currently affected by type 2 diabetes, which is closely linked with obesity. In the type 2 form of the disease, people gradually develop resistance to insulin or fail to produce enough of the hormone, resulting in rising blood sugar levels.

That can lead to other health problems, such as heart disease, vision problems and neural or kidney dysfunction.

The FDA urges that the new medications be used in combination with a healthy diet and exercise to help bring diabetes under control. All of the drugs underwent study either as stand-alone products or used alongside standard diabetes medications such as sulfonyureas or insulin.

In the case of Nesina, the drug showed safety and effectiveness across 14 clinical trials, involving more than 8 500 patients, according to the FDA. The most common side effects included stuffy or runny nose, headache, and upper respiratory tract infections.

Patients in the trial

Kazano's safety and effectiveness were tested in four clinical trials involving more than 2 500 patients. Side effects included those seen with Nesina, as well as diarrheao, high blood pressure and back pain, the FDA said.

The agency is also requesting that a "boxed warning" be included on Kazano's labelling, highlighting the potential risk of lactic acidosis (lactic acid buildup in the blood), which can occur in products containing metformin.

Oseni was studied in four clinical trials involving more than 1 500 patients, the FDA noted. Side effects were similar to those seen with Nesina, as well as back pain. Oseni's labelling will also carry a boxed warning, this time cautioning users about the risk for heart failure that accompanies drugs containing pioglitazone.

The drugs will also be subject to what are known as "post-marketing studies," aimed at spotting any emerging risks. For example, studies looking at heart and liver issues are mandated for Nesina, while studies focused on potential liver and pancreas problems are mandated for both Kazano and Oseni, the FDA said.

All three drugs are distributed by Takeda Pharmaceuticals America Inc., of Deerfield, Ill.

Read more:

Diabetes: type 2

Treatment plan: type 2 diabetes

Sleep reduces risk of type 2 diabetes

More information

Find out more about type 2 diabetes at the American Diabetes Association.

 

(Copyright © 2013 HealthDay. All rights reserved.) 

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Add your comment
Comment 0 characters remaining

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules